Avid Bioservices Inc (CDMO)

[biopharm]

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer
Open

R B Birge1,10,
S Boeltz2,10,
S Kumar1,10,
J Carlson3,10,
J Wanderley4,10,
D Calianese1,10,
M Barcinski5,10,
R A Brekken6,7,10,
X Huang6,7,10,
J T Hutchins3,10,
B Freimark3,10,
C Empig3,10,
J Mercer8,10,
A J Schroit9,10,
G Schett2,10 and
M Herrmann2,10

1Department of Microbiology, Biochemistry and Molecular Genetics, Cancer Center, Rutgers New Jersey Medical School, 205 South Orange Ave, Newark, NJ 07103, USA

2Department of Internal Medicine 3—Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), University Hospital Erlangen, 91054 Erlangen, Germany

3Peregrine Pharmaceuticals, 14282 Franklin Avenue, Tustin, CA 92780, USA

4Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

5Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

6Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, Dallas, TX 75390-8593, USA

7Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA

8Medical Research Council Laboratory for Molecular Cell Biology, University College London, Gower Street, London WC1E 6BT, UK

9Simmons Cancer Center and the Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA

10These authors contributed equally to this work.

The large amount of evidence obtained with AnxA5 and PS-targeting antibodies supports the notion that PS is a fundamental immune checkpoint akin to or upstream of the CTLA4 and PD-1/PD-L1 checkpoints. Late-stage clinical trials evaluating the PS-targeting antibody, bavituximab, are in progress in multiple oncology indications, while agents targeting PS receptors are in various stages of pre-clinical and clinical development.

Some should start paying attention and if one wonders why everything is so hush hush, maybe there is a very good reason and I have started collecting a few names with private profiles... tied to PS Targeting.... and I guess we will start here

This can be listed under, another type of intangible piece of the puzzle that continues to point towards big things up and coming for PS Targeting. This little list below wouldn't make much sense to one that never searches and sifts through puzzle pieces, but when we have Martin Herrmann all of a sudden in the SPOTLIGHT with PS Targeting folks...

all one can do is wonder who is behind the private profiles

-------------------------

Martin Herrmann

Top co-authors
View all


Private Profile

Reinhard E Voll (92)
University Medical Center Freiburg

Private Profile

Georg Schett (55)
Universitätsklinikum Erlangen

Benjamin Frey (44)
Universitätsklinikum Erlangen

https://www.researchgate.net/profile/Martin_Herrmann4